186,967 research outputs found
Mirone di Priene e i suoi Messeniaka
No full textI Messeniaka di Mirone di Priene sono conosciuti soprattutto grazie a Pausania (libro IV), che utilizza tale opera come fonte per la storia della prima guerra messenica. Tuttavia, tra gli studiosi moderni non esiste accordo unanime su quali fossero i contenuti dei Messeniaka. Il presente lavoro, dunque, passa in rassegna le testimonianze letterarie su Mirone e sui Messeniaka, al fine di tracciare il profilo dell’autore e capire quali fossero i contenuti della sua opera
Editorial Comment from Dr Mirone et?al. to Resiniferatoxin for treatment of lifelong premature ejaculation: A preliminary study.
No full text
Are We Finally on the Right Track in Treating "Difficult" Erectile Dysfunction Patients?
No full textPenile implants in the era of oral drug treatment for erectile dysfunction.
No full textThe advent of phosphodiesterase type 5 inhibitors (PDE5-I) has revolutionized the management of patients with erectile dysfunction (ED) of various causes. Currently, all patients with ED should be assessed with a thorough medical and sexual history, physical examination and selected blood tests, including serum glucose, lipid profile, morning total testosterone and prolactin [ 1]. At the end of this initial assessment phase most patients may be counselled on the different treatment options available and oral drug therapy results as most frequently chosen by current patients [ 2]. Patients who do not respond to oral drug therapy and those who cannot use PDE5-I because of specific contraindications may be given the option to be treated with either intracavernosal or intraurethral medical therapy, or with a vacuum device. Penile implants are usually considered as an option for patients who fail to respond to any kind of non-surgical therapy. Although this group of patients is much smaller than the overall population of patients with ED seeking medical advice, it is also becoming evident that with increasing knowledge of the efficacy and safety of oral drug therapy for ED, there has been a progressive increase of the number of office visits for this medical condition, and the final result includes a proportional increase of the number of those not responding to nonsurgical therapies. Thus the number of potential candidates for a penile implant has certainly increased in the recent past, in the experience of most urologists who work in andrology referral centres. This is the main reason why penile prostheses are important in treating ED. In this article we review the critical aspects of patient selection criteria, types of implants available and criteria leading to a specific choice, preoperative management of the patient, surgical technique, postoperative management, long-term results, and the management of complications. We consider that every resident should be knowledgeable on this list of topics. This review was based on a Medline search for a full-length reports in English, published from January 2000 to April 2004. The key words 'penile implants', 'penile prostheses', and 'erectile dysfunction' were used in the search. Updated information on the various types of implants was collected from the websites of the companies manufacturing these prostheses. OI MIRONE, Vincenzo/0000-0002-7639-2560; Gallina, Andrea/0000-0002-4540-956
A prospective observational cohort study on patients with PSA levels ranging from 4 to 10 ng/ml at opportunistic screening: Management and responses to ciprofloxacin 1000 mg
No full textObjective: To analyze in the real life clinical setting the effect of fluorchinolones treatment in the management of elevated (4-10 ng/ml) prostate-specific antigen level we conducted an observational prospective cohort study. Material and methods: Eligible for the study were subjects aged 45-75 years with a PSA level 4-10 ng/ml, consecutively observed during their routine practice by first level outpatients urologic centres. Results: A total of 740 patients, mean value of total PSA at study entry: 5.8 (SD = 1.6) entered the study. A total of 616 subjects were treated with ciprofloxacin. The mean serum t-PSA value decreased between study entry and final visit of 1.31 ng/ml (SD 4.19) (p < 0.05). At follow up visit the 49.4% (95% CI 44.1-55.5) of patients had PSA level < 4 ng/ml. In comparison with patients with t-PSA < = 5.0 ng/ml, the OR of having normal t-PSA value at follow up were respectively 0.61 (95% CI 0.4-0.9) and 0.23 (0.1-0.3) for patients with t-PSA 5.1-6.2 and ≥ 6.3. Conclusion: The results of this large observational prospective study showed that a 2-3 week course of treatment with ciprofloxacin 1000 mg is able to significantly reduce the PSA level in about 50% of men aged 45-75 years with t-PSA levels of 4-10 ng/ml
Peyronie's disease and autoimmunity-a real-life clinical study and comprehensive review
No full textIntroduction: Although heavily investigated over the last decades, Peyronie's disease (PD) pathogenesis remains unclear. Aim: We sought to investigate the association between PD and autoimmune diseases (ADs) in men seeking medical help for sexual dysfunction in the real-life setting. Methods: Complete sociodemographic and clinical data from a homogenous cohort of 1,140 consecutive Caucasian-European men were analyzed. Health-significant comorbidities were scored with the Charlson Comorbidity Index and ADs were stratified according to International Classification of Diseases, Ninth Revision classification. Main Outcome Measures: Descriptive statistics and multivariate logistic regression models tested the association between ADs and PD. Results: PD was diagnosed in 148 (13%) of the 1,140 men; of PD patients, 14 (9.5%) had a comorbid AD; conversely, the rate of ADs in non-PD patients was significantly lower (χ2=24.7; P<0.01). Both patient age and AD comorbidity achieved multivariable independent predictor status for PD (odds ratio [OR]: 1.05; P<0.01 and OR: 4.90; P<0.01, respectively). Conclusions: Our observational findings showed that ADs are highly comorbid with PD in a large cohort of same-race individuals seeking medical help for sexual dysfunction in the real-life setting. Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, Russo A, Capitanio U, Briganti A, Cantiello F, Mirone V, Damiano R, Montorsi F, and Salonia A. Peyronie's disease and autoimmunity-A real-life clinical study and comprehensive review. J Sex Med 2015;12:1062-1069
La riattribuzione chirurgica di sesso (RCS) nei transessualismi andro-ginoidi: confronto fra due tecniche
No full text
A prospective observational cohort study on patients with PSA levels ranging from 4 to 10 ng/ml at opportunistic screening : management and responses to ciprofloxacin 1000 mg
No full textObjective: To analyze in the real life clinical setting the effect of fluorchinolones treatment in the management of elevated (4-10 ng/ml) prostate-specific antigen level we conducted an observational prospective cohort study.
Material and methods: Eligible for the study were subjects aged 45-75 years with a PSA level 4-10 ng/ml, consecutively observed during their routine practice by first level outpatients urologic centres.
Results: A total of 740 patients, mean value of total PSA at study entry: 5.8 (SD = 1.6)) entered the study. A total of 616 subjects were treated with ciprofloxacin. The mean serum t-PSA value decreased between study entry and final visit of 1.31 ng/ml (SD 4.19) (p < 0.05). At follow up visit the 49.4% (95% CI 44.1-55.5) of patients had PSA level < 4 ng/ml. in comparison with patients with t-PSA < = 5.0 ng/ml, the OR of having normal t-PSA value at follow up were respectively 0.61 (95%CI 0.4-0.9) and 0.23 (0.1-0.3) for patients with t-PSA 5.1-6.2 and ≥ 6.3, in comparison with those with t-PSA < = 5.0.
Conclusion: The results of this large observational prospective study showed that a 2-3 week course of treatment with ciprofloxacin 1000 mg is able to significantly reduce the PSA level in about 50% of men aged 45-75 years with t-PSA levels of 4-10 ng/ml
- …
